What makes Woodford such a potent figure is the example he sets in backing global drug development, where even small companies knit together scientific, administrative and support functions from an international cast of players.
Promethera Biosciences has put together €25.3 million ($31.4 million) in equity and loans to hit the gas on its stem cell treatment for rare liver diseases.
London's Cell Medica has raised a £50 million ($78 million) B round to support its work on treatments that train the body's immune system to fight cancer and infectious disease, rolling through midstage trials with an oncology candidate.
High-profile U.K. investor Neil Woodford made headlines last week when he invested $25 million into Northwest Biotherapeutics, and that's a sign of much more to come, according to reports, as the ex-Invesco manager is planning to unveil a new fund devoted solely to emerging biotechs.
Proponents of DNA printing have heralded it as a way to do everything from bringing alien life back from Mars to delivering vaccines in the event of a pandemic. And the technology has attracted GlaxoSmithKline and Roche, both of which have taken an interest in Cambrian Genomics.
BioNano Genomics has restocked its coffers to fund an assault on the genome analysis sector. The San Diego, CA-based genome mapping firm raised a $53 million war chest from Novartis' venture fund and other investors to accelerate uptake of its Irys DNA analysis device and accompanying software.
San Diego's BioNano Genomics has raised a $53 million C round to bankroll its efforts to decode the so-called inaccessible genome, adding Novartis to its investor syndicate as it works to amplify its profile.
U.K. biotech investment heavyweight Neil Woodford has invested $25 million in the U.S. biotech Northwest Biotherapeutics, gambling that its controversial Phase III study on a new therapeutic vaccine for brain cancer comes up a winner.
In what will likely be the most closely watched IPO in biotech, Juno Therapeutics has rolled out a $150 million offering that is likely to make a big splash on the market.
Third Rock Ventures startup Blueprint Medicines has hauled in a $50 million C round, cash that'll see its way through clinical trials and keep its promising platform generating new candidates.